<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980031</url>
  </required_header>
  <id_info>
    <org_study_id>07-14634</org_study_id>
    <nct_id>NCT00980031</nct_id>
  </id_info>
  <brief_title>Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension</brief_title>
  <acronym>Aldosterone</acronym>
  <official_title>Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Creighton University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to investigate the effects that the addition of aldosterone
      blockade with eplerenone will have on the progression of diastolic dysfunction in patients
      with controlled essential hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this project is to determine if eplerenone, an aldosterone blocker, prevents
      remodelling of the heart in patients with controlled essential hypertension, defined as
      having a blood pressure of equal to or less than 130/80 in diabetics and equal to or less
      than 140/90 in non-diabetics. This study will investigate if the addition of 25 milligrams of
      eplerenone daily to a subject's hypertension medication regimen will prevent the progression
      or development of diastolic dysfunction. Echocardiography will be used to measure the changes
      in heart structure of subjects receiving eplerenone versus subjects receiving placebo (a drug
      that may resemble the study drug but contains no active ingredient). Approximately 30
      subjects will take part in this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding ended prior to study completion
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Remodeling (cardiac chamber sizes, wall thickness, left ventricular ejection fraction, left atrial volumes, and diastolic function) assessed by transthoracic echocardiogram</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Myocardial Remodeling</condition>
  <arm_group>
    <arm_group_label>Lactose Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Compounded capsule using Lactose Monohydrate Powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 mg tablet placed in a capsule filled with Lactose Monohydrate Powder.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>25mg PO daily (QD)for 6 months</description>
    <arm_group_label>Eplerenone</arm_group_label>
    <other_name>Inspra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactose Tablet</intervention_name>
    <description>Lactose tablet</description>
    <arm_group_label>Lactose Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treated and controlled hypertension

          -  Less than 140/90 in non-diabetics

          -  Less than 130/80 in diabetics

        Exclusion Criteria:

          -  currently receiving an aldosterone blocker

          -  clinical evidence of congestive heart failure

          -  prior myocardial infarction

          -  renal dysfunction with a creatinine clearance of less than 40ml/min

          -  serum potassium &gt; 5.5meq/L at initiation

          -  concomitant use of a medication that inhibits the CYP3A4 enzyme (ketoconazole,
             itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M Jeff Holmberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Creighton Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Creighton University Medical Center (including ambulatory centers)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2009</study_first_posted>
  <last_update_submitted>March 27, 2014</last_update_submitted>
  <last_update_submitted_qc>March 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aldosterone Blockade</keyword>
  <keyword>Aldosterone Receptor Blockers</keyword>
  <keyword>cardiac chamber size</keyword>
  <keyword>wall thickness</keyword>
  <keyword>left ventricular ejection fraction</keyword>
  <keyword>left atrial volumes</keyword>
  <keyword>diastolic function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

